- Company to Highlight Data for its Two Newest Urological Products -
CORONA, Calif., April 22 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI), a global leader in the development and distribution of pharmaceuticals, announced today that management will host and webcast a meeting for the investment community at the American Urological Association (AUA) Annual Meeting taking place in Chicago, Illinois, April 25-30, 2009.
The company will be hosting the meeting to review new data on its two newest brands, RAPAFLO (silodosin) and GELNIQUE (oxybutynin chloride) Gel 10%, including:
The event will be held on Monday, April 27, 2009, from 3:00 p.m. to 5:00 p.m. (CDT) at The Hyatt McCormick in Conference Center Room 12D, adjacent to the McCormick Center, where the AUA meeting is being held. To participate in the event in person, please RSVP to Scott Anderson, Watson Pharmaceuticals, by Friday, April 24, via e-mail, firstname.lastname@example.org, or phone, (951) 493-9684.
The presentation will be webcast live and can be accessed on Watson Pharmaceuticals' Investor Relations Web site at http://ir.watson.com. Pre-registration is not required to view the webcast. An archived version will be available for 30 days after the live presentation and can be accessed at the same location.
About Watson Pharmaceuticals, Inc.
Watson Pharmaceuticals, Inc. is a global leader in the development and distribution of pharmaceuticals with a broad portfolio of generic products and a specialized portfolio of branded pharmaceuticals focused on Urology, Women's Health and Nephrology (Medical).
In the U.S., the Watson portfolio includes RAPAFLO, GELNIQUE, TRELSTAR(R) LA and TRELSTAR(R) Depot, Ferrlecit(R), INFeD(R), and Oxytrol(R). In addition, Watson markets the following brands under co-promotion agreements: AndroGel(R), with Solvay Pharmaceuticals, Inc.; and Femring(R), with Warner Chilcott Limited. The Watson pipeline portfolio includes a number of products, including a six-month formulation of TRELSTAR(R), for the treatment of advanced prostate cancer which is currently under review by the FDA; URACYST(R), under development for cystitis; and a novel new oral contraceptive.
Any statements contained in this press release that refer to future events or other non-historical facts are forward-looking statements that reflect Watson's current perspective of existing trends and information as of the date of this release. Except as expressly required by law, Watson disclaims any intent or obligation to update these forward-looking statements. Actual results may differ materially from Watson's current expectations depending upon a number of factors affecting Watson's business. These factors include, among others, the impact of competitive products and pricing; market acceptance of and continued demand for Watson's products, including GELNIQUE and RAPAFLO; difficulties or delays in manufacturing; the difficulty of predicting the timing or outcome of FDA or other regulatory agency approvals or actions, if any; patents and other intellectual property rights held by the Company and the ability to successfully enforce such rights against third parties; and other risks and uncertainties detailed in Watson's periodic public filings with the Securities and Exchange Commission, including but not limited to Watson's Annual Report on Form 10-K for the year ended December 31, 2008.
|SOURCE Watson Pharmaceuticals, Inc.|
Copyright©2009 PR Newswire.
All rights reserved